; Whereas weak health systems that fail to prevent unnecessary deaths also lack the staff, health facility infrastructure, and medical technologies required for effective care delivery and thereby disease containment, thus placing all countries at increased risk of pandemic disease; Whereas essential medical technologies such as diagnostics, treatments, and vaccines for diseases that affect the global poor are frequently unavailable or inaccessible to health systems in developing countries because— (1) investing in research and development for technologies for diseases that disproportionately affect the global poor is often unprofitable for pharmaceutical corporations; (2) high intellectual property licensing fees from originator companies to generic manufacturers price the global poor out of access to medical technologies; and (3) originator technology companies refuse to share or license intellectual property to generic manufacturers, which results in limited supply and high prices, as in the case of COVID–19 vaccines; Whereas the Lancet Commission on Investing in Health estimates the additional annual spending required to prevent the vast majority of the millions of unnecessary deaths and confer essential universal health coverage in low- and lower-middle-income countries is $75,000,000,000 and $293,000,000,000 (in 2016 United States dollars), respectively, representing just— (1) 1.6 percent of the United States gross domestic product (GDP) in 2021; (2) 0.5 percent of G20 GDP in 2021; and (3) 2.8 percent of the wealth possessed by the world’s billionaires in 2021; Whereas regular annual United States appropriations for global health have increased by merely 10.6 percent to $11,300,000,000 since 2010, and have been outpaced by both inflation and the United States economic growth